- Leading institutional investors commit $95 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Fidelity Management & Research Company LLC, ...

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its ...

FS Development II, the second blank check company formed by Foresite Capital targeting a healthcare business, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

Leading institutional and strategic investors commit $75 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Gilead Sciences, RA Capital ...

PHILADELPHIA and NEW YORK, Dec. 18, 2019 /PRNewswire/ -- FS/KKR Advisor, LLC (FS/KKR), a partnership between FS Investments and KKR Credit Advisors (US) LLC, today announced the closing of the mergers ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...